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Energy homeostasisAutophagy is a catabolic pathway essential for cellular energy homeostasis that involves the self-degradation
of intracellular components in lysosomes. This process has been implicated in the pathophysiology of many
human disorders, including infection, cancer, and ﬁbrosis. Autophagy is also recognized as a mediator of
survival and proliferation, and multiple pathways induce autophagy under conditions of cellular stress,
including nutrient and energy depletion. High autophagic activity has been detected in ﬁbrogenic cells
from several tissues; however the role of autophagy in ﬁbrogenesis and mesenchymal cells varies greatly
in different tissues and settings, with contributions uncovered to energy metabolism and collagen turnover
by ﬁbrogenic cells. Because several chemical modulators of autophagy have already been identiﬁed, autophagy
regulation constitutes a potential target for antiﬁbrotic therapy. This article is part of a Special Issue entitled:
Fibrosis: Translation of basic research to human disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mesenchymal cells' physiologic healing response to injury entails
the formation of scar tissue. If the injury persists, this wound healing
response leads to ﬁbrogenesis and extracellular matrix accumulation.
Although there are organ-speciﬁc differences in ﬁbrogenic pathways,
certain core elements characterize the ﬁbrogenic response in almost
all tissues. Damage to the epithelium or endothelium, instigated by
infection, autoimmune processes, toxins, or mechanical disturbance,
triggers the release of inﬂammatory mediators and initiation of the
ﬁbrogenic response.
Despite signiﬁcant progress made in elucidating the mechanisms
of ﬁbrogenesis, new components of the ﬁbrotic machinery continue to
be unearthed, and effective antiﬁbrotic therapies remain elusive [1,2].
Cells respond to changes in the microenvironment through alter-
ation of their anabolic and catabolic pathways. Autophagy is a cata-
bolic pathway essential for cellular homeostasis that involves the
self-degradation of intracellular components in lysosomes as part of
cytoplasmic turnover. Autophagy has been implicated in the patho-
physiology of many human disorders including ﬁbrotic diseases.
Here we review its role in the activation of mesenchymal cells in
the context of ﬁbrosis.
There are three types of autophagywhich differ in themechanismby
which they deliver materials to the lysosomal lumen: microautophagy,s: Translation of basic research
ool of Medicine, 1425 Madison
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man).
l rights reserved.chaperone-mediated autophagy andmacroautophagy.Macroautophagy
is the most prevalent form and unless otherwise speciﬁed, the term
autophagy used in this paper refers to it.
Microautophagy is a poorly understood process in mammalian
cells in which the material to be degraded is engulfed by direct invagi-
nation of the lysosomal membrane.
Chaperone-mediated autophagy is a more selective process by
which cytosolic proteins marked by the pentapeptide motif KFERQ
bind the lysosomal membrane through the lysosomal membrane
receptor LAMP-2a (lysosomal-associated membrane protein 2a).
Once translocated to the lumen, proteins are degraded by lysosomal
hydrolases.
In macroautophagy, hereafter referred to as “autophagy,” the cyto-
plasmic component is surrounded by an expanding membrane sac,
termed the phagophore,which elongates until its two edges fuse, forming
a double membrane vesicle called an autophagosome. The outer mem-
brane of the autophagosome then fuses with the lysosome generating
the autolysosome or autophagolysosome and the lysosomal enzymes de-
grade the inner membrane together with sequestered material [3].
2. Autophagy machinery
Autophagy is a conserved and ubiquitous pathway essential for
maintaining cellular energy homeostasis. Under normal conditions
autophagic activity proceeds at a very low level, and is tightly regulated
following induction in many cellular stress conditions. There have
been tremendous advances in our knowledge of the molecular mecha-
nism of autophagy in recent years, in particular the discovery of the
autophagy-related genes (Atg). These 14 genes, conserved between
yeast and humans, are required for autophagosome formation and reg-
ulate the formation of the core autophagicmachinery [4]. The autophagy
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selection, vesicle formation, autophagosome formation, fusion and
breakdown.
In unstressed conditions, autophagy levels are low and are
efﬁciently inhibited by the serine/threonine protein kinase mTOR
(mammalian target of rapamycin). In mammals, mTOR inactivates the
complex formed by the Unc-51-like kinases 1 (ULK1), and 2 (ULK2),
the focal adhesion kinase family-interacting protein of 200kD (FIP200)
and Atg13 (ULKs–Atg13–FIP200 complex). However upon mTOR inhi-
bition, ULK1 and ULK2 are activated and phosphorylate Atg13–FIP200,
leading to a conformational change essential to autophagy induction [5].
Induction of autophagy provokes formation of the autophagosome.
The origin of the autophagosome membrane is a matter of debate and
available data supports three potential sources: endoplasmic reticu-
lum (ER) [6], mitochondrial membrane [7] and plasmamembrane [8].
The cargo to be degraded has to be recognized by the autophagy
machinery. In mammals this selection process is mediated by the
cytosolic adaptor protein P62/sequestosome 1. P62 binds by its
ubiquitin-associated domain to the microtubule-associated protein 1
light chain 3 (LC3) and delivers the ubiquitinated cargo for autophagic
degradation [9]. The formation of the autophagosome requires the
class III phosphatidylinositol 3-kinase (PI3K) macromolecular complex,
composed of the PI3K vacuolar protein sorting 34 (Vps34), beclin1, Atg
14 and p150. Beclin 1 can enhance Vps34 activity; however, under
homeostatic conditions it is inactivated through its binding to the
anti-apoptotic protein Bcl2 (B-cell lymphoma/leukemia-2) [10]. The
PI3K complex recruits two interconnected ubiquitin-like (Ubl) conjuga-
tion complexes that share a single E1-like activating enzyme, Atg7
[3]. These Ubl complexes are essential for autophagosome formation
(Atg12–Atg5–Atg16L1) and elongation (Atg8–LC3) respectively. Atg7
activates Atg12 and is then transferred to Atg10 and attached covalently
to Atg5. The Atg12–Atg5 complex then conjugates with Atg16L1 and
attaches to the phagophore (Fig. 1).
In the second Ubl conjugation, the LC3 precursor is cleaved by
Atg4 and converted to LC3-I. Atg7 and Atg3 promote the conjugation
of LC3-I to phosphatidylethanolamine to form LC3-II, a process that is
facilitated by the Atg12–Atg5–Atg16L1 complex. Although it is even-
tually delipidated by Atg4 and recycled, LC3-II is a useful marker of
the autophagy membrane as it remains on the inner and outer mem-
brane of the autophagosome until its fusion with the lysosomes [11].
After fusion, the acidic lysosomal hydrolases degrade the sequestered
materials [12]. Finally, the resultant small molecules are transported
back to the cytosol for maintenance of cellular homeostasis.
3. Autophagy regulation
3.1. Signaling pathways regulating autophagy
3.1.1. mTOR dependent regulation
Autophagy is strongly induced under stress conditions such as
amino acid starvation and ATP depletion. This nutrient-sensitive in-
duction is mediated in part through the mTOR pathway. The mTOR
pathway is composed of the rapamycin-sensitive mTOR complexes
(mTORC) 1 and 2, although only mTORC1 is a direct regulator of
autophagy [13]. Under nutrient-rich conditions, mTORC1 phosphory-
lates and inhibits the ULKs–Atg13–FIP200 complex and autophagy is
kept at very low levels. In situations of metabolic stress, mTORC disso-
ciates from the complex, leading to dephosphorylation-dependent
activation of ULKs and subsequent induction of autophagy [5]. A
major signaling pathway regulating mTORC1 is the PI3K complex. Dif-
ferent members of the PI3K complex have discrete roles in autophagy
modulation. The class I PI3K acts through Akt activation and suppresses
autophagy [14]; however the class III PI3K, Vps34, stimulates autophagy
by increasing local concentrations of phosphatidylinositol 3-phosphate
(PI3P) [15]. Besides PI3K, other kinases can modulate autophagy
throughmTOR, including AdenosineMonophosphate-Activated ProteinKinase (AMPK) [16], IκB kinase [17] and the members of the mitogen-
activated protein kinase (MAPK) pathway (ERK [18], p38 [19], JNK
[20]) (Fig. 2).
3.1.2. mTOR independent regulation
Although the mTOR pathway is the most studied and best-
characterized autophagy regulatory pathway, mTOR-independent
regulation has also been described.
Autophagy is negatively regulated by intracellular inositol and inosi-
tol 1,4,5-triphosphate (IP3). IP3 binds to its receptor on the ER and
releases the stored Ca2+ into the cytoplasm, which provokes several
cellular responses and inhibits autophagy [21,22]. cAMP and cytosolic
Ca2 downregulates autophagy through the cAMP–Epac–PLC-ε–IP3 [22]
and Ca2+–calpain–Gsα [23] pathways, respectively (Fig. 3).
3.2. Transcriptional regulation
Although not much is known about the transcriptional regulation
of autophagy, some autophagy genes such as lc3 are rapidly up-
regulated. The transcription factor FoxO3 induces transcription
of several autophagy genes including lc3, atg12, atg4 and beclin 1
[10]. In yeast, atg1 and atg13 have been recognized as targets of the
transcriptional factor GCN4 [24].
3.3. Post-translational regulation
Recent studies have shown that post-translational modiﬁca-
tions modulate the autophagic ﬂow [25]. As mentioned before
ubiquitylation of the autophagic cargo and ubiquitylation-like
conjugation of the Atg12–Atg5–Atg16L1 and Atg8–LC3 complexes
are essential autophagy triggers. Postranscriptional lipidation of
LC3 also induces autophagosome formation. Phosphorylation also
plays an important role in autophagy regulation. Phosphorylation
of either Bcl-2 or Beclin 1 reduces Bcl2-Beclin1 interaction and in-
duces autophagy [26]. Phosphorylation of ULK1 and dephosphoryla-
tion of Atg13 are also essential for autophagy initiation [25].
Acetylation of Atg proteins by acetyltransferases also modiﬁes
autophagy. Atg7 interaction with p300 maintains the acetylation of
Atg5, Atg7, Atg8 and Atg12 proteins, thereby suppressing autophagy
[27]. Upon metabolic stress conditions, p300 dissociates from Atg7
and the deacetylase Sirt1 removes the acetyl groups from Atg7, Atg5,
Atg8 and Atg12 and triggers autophagy [28] (Fig. 4). TIP60 is another
acetyltransferase that has been recently identiﬁed as a positive regula-
tor of autophagy through its interaction with ULK [29].
4. Autophagy measurement
The accurate measurement of autophagy is a critical and contro-
versial issue, especially because autophagy is a dynamic process
with several steps that can be individually regulated. The main issue
is the differentiation between formation and accumulation of
autophagosomes. Measurement of the autophagic ﬂux constitutes
the most accurate quantiﬁcation of the complete process, including
the delivery of cargo to lysosomes and its breakdown and recycling
[30]. Here we review some of the recommended methods for moni-
toring autophagy. However, the absence of an approach with high
sensitivity and speciﬁcity necessitates the combination of at least
two of the methods discussed here.
Electron microscopy (EM) is one of the most sensitive techniques
to detect the presence of autophagic vacuoles (AV). EM permits the
visualization of the entire maturation process from the formation
of the phagophore to the assembly of the autophagolysosome [31].
Quantiﬁcation of the AV is required; the preferred method is to quan-
tify autophagosome volume as the percent of cytoplasmic volume.
Immuno-EMwith gold-labeling using antibodies to cargo proteins in-
creases speciﬁcity and facilitates quantiﬁcation [32].
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Fig. 1. Autophagosome formation. Autophagosome formation requires the ULK1/2–mAtg13–FIP200 complex as well as the class III phosphatidylinositol 3-kinase (PI3K)macromolecular
complex, which is composed of the PI3K vacuolar protein sorting 34 (Vps34), beclin1, Atg 14 and p150. This complex recruits two interconnected ubiquitin-like (Ubl) conjugation
complexes that are essential for autophagosome formation (Atg12–Atg5–Atg16L1) and elongation (Atg8–LC3) respectively. Although it is eventually delipidated by Atg4 and recycled,
LC3-II is a useful marker of the autophagy membrane because it remains on the inner and outer membrane of the autophagosome until its fusion with the lysosomes. After fusion, the
acidic lysosomal hydrolases degrade the engulfed materials. The resultant small molecules are ﬁnally transported back to the cytosol for maintenance of cellular homeostasis. The origin
of the autophagosome membrane remains unknown, although the plasma membrane, endoplasmic reticulum, and mitochondrial membrane have all been implicated.
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Detection of LC3-II is a reliable marker of autophagy, as it is localized
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Fig. 3. mTORC-independent regulation of autophagy. Inositol 1,4,5-triphosphate (IP3) mediates mTORC-independent regulation of autophagy. IP3 binding to the endoplasmic
reticulum (ER) instigates the release of calcium into the cytoplasm. Binding of agonists to L-type calcium channels also increases the cytoplasmic levels of calcium. The increase
in cytoplasmic calcium induces the activation of a family of calcium-dependent cysteine proteases called calpains. Activated calpains cleave and activate Gsα, which induces
adenylyl cyclase activity to increase the concentration of cAMP. Elevated cAMP activates the Epac molecule, which activates phospholipase C (PLC)-ε and increases IP3, thereby
completing this regulatory loop.
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interpretation. An increase in LC3 levels can be due either to an increase
in autophagosome synthesis or to reduced turnover. To better interpret
the changes, autophagy ﬂux should be measured after preventing lyso-
somal degradationwith protease inhibitors (leupeptin), drugs that alter
the lysosomal pH (baﬁlomycin A, chloroquine), or agents that block the
fusion of autophagosomes with lysosomes. In the presence of such in-
hibitors, an accumulation of LC3-II would indicate a deﬁcient
autophagic ﬂux, whereas a failure of LC3 to increase would indicate a
defect earlier in the process [34].p300 Atg7
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Metabolic
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Autophagy
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Fig. 4. Post-translational modiﬁcation of autophagy. Autophagy is subject to post-translation
phosphorylation of ULK1/2 and of the Atg13–FIP200 complex. Acetylation of Atg proteins by
acetylation of Atg5, Atg7, Atg8 and Atg12 proteins, thereby suppressing autophagy. Upon me
the acetyl groups from Atg7, Atg5, Atg8 and Atg12 and triggers autophagy.LC3 can also be detected by direct ﬂuorescence microscopy by
tagging it to a ﬂuorescent protein such as GFP (GFP-LC3). Quantiﬁca-
tion of the number of ﬂuorescent punctae per cell is an accurate and
useful approach [30].
As the mTOR pathway is one of the most important autophagy
regulators, measurement of mTORC1 activity via quantiﬁcation of the
phosphorylation of its downstream targets (p70S6 and S6 protein)
has been proposed as a potential method to monitor autophagy [35].
Nonetheless, it should be taken into account that there are mTOR-
independent mechanisms that also induce autophagy. 
p300
Atg7
Atg8
Atg5Atg12
Phagophore formation
ts
al modiﬁcation. As depicted in Fig. 2, activated mTORC1 suppresses autophagy through
acetyltransferases also modiﬁes autophagy. Atg7 interaction with p300 maintains the
tabolic stress conditions, p300 dissociates from Atg7 and the deacetylase Sirt1 removes
Table 2
Inhibitors of autophagy and their current clinical applications.
976 M. Hilscher et al. / Biochimica et Biophysica Acta 1832 (2013) 972–978As most of the Atg genes do not show signiﬁcant changes in mRNA
levels upon autophagy induction [36], protein quantiﬁcation is a better
readout.
The p62 protein binds strongly to LC3 as well as to ubiquitinated
substrates and ismainly degraded through autophagy; therefore, inhi-
bition of autophagy causes its accumulation. Detection of endogenous
p62 by Western blot is useful to monitor autophagy ﬂux. However,
p62 detection is recommended in conjunction with another method
as inhibition of the proteasome also induces its accumulation [37].
The autophagosome maturation process can be also monitored
using a tandem RFP-GFP-tagged LC3 [38]. The RFP signal is resistant
to the acidic/proteolytic conditions of the lysosome lumen, whereas
GFP is sensitive. Therefore, the co-localization of both GFP and RFP
indicates the absence of contact with the lysosomal compartment.
On the other hand, expression of RFPwithout GFP signals the presence
of an autolysosome.
Generation of transgenic GFP-LC3 mice with basal GFP-LC3 ex-
pression that can be further induced under conditions that activate
autophagy has led to the capability to monitor autophagy in vivo
[39]. For a more extensive review of the use and interpretation of
assays for monitoring autophagy see reference [28].
5. Autophagy and mesenchymal cells
Recent studies implicate autophagy in the pathogenesis ofmultiple
diseases, including infection, cancer, and neurodegenerative disease.
Autophagy is increasingly recognized as a mediator of survival and
proliferation, although its role in ﬁbrogenesis varies greatly in different
tissues and settings. Little is known about the role of autophagy in the
regulation of mesenchymal cell differentiation into myo!broblast-like
cells, and there is evidence suggesting that this role may differ from
its role in epithelial cells [40,41] (Table 1).
Here we review the still scarce knowledge of the role of autophagy
in mesenchymal cells.
Autophagy has been shown to play a crucial role in the survival of
primary human ﬁbroblasts [42] and high levels of autophagy have
been reported in ﬁbrogenic cells in almost every tissue: stellate cells
[40,43], cardiac ﬁbroblasts [41,44], mesangial cells [45], dermal ﬁbro-
blasts [46], and synovial ﬁbroblasts [47].
In the liver, injury of any kind leads to the transdifferentation
of quiescent stellate cells into myoﬁbroblast-like cells that are key
players in the wound-healing response. Activation of stellate cells
leads to the deposition of massive quantities of extracellular matrix
(ECM) that over time culminates in hepatic ﬁbrosis. Our group re-
cently reported that autophagy provides cellular energy to fuel the
catabolic pathways of cellular activation [40]. Indeed, autophagy inhi-
bition in the liver ﬁbrogenic cells leads to an impairment of activation
and subsequent reduction in ECM deposition [40].We reproduced this
effect on the ﬁbrogenic response by blocking autophagy in ﬁbrogenic
cells from kidney and lung, suggesting that autophagy may comprise
a core pathway of ﬁbrogenesis and an attractive targetable antiﬁbrotic
candidate.Table 1
The role of autophagy according to mesenchymal cell type.
Mesenchymal cell type Role of autophagy
Hepatic stellate cells
[40,43],
Fuels catabolic pathways of cellular activation and
thereby promotes acquisition of a ﬁbrogenic phenotype
Scleroderma ﬁbroblasts
[46]
Provides energy to fuel acquisition of a ﬁbrotic
phenotype
Synovial ﬁbroblasts [47] Pro-survival pathway that perpetuates injury
Cancer-associated
ﬁbroblasts [50,51]
Generates high energy nutrients that feed adjacent
cancer cells and promotes tumor growth,
proliferation, and metastasis
Cardiac ﬁbroblasts [41,44] Ameliorates ﬁbrosis by promoting collagen degradation
Kidneymesangial cells [45] Ameliorates ﬁbrosis by promoting collagen degradationSimilar data have been reported in skin ﬁbrosis [46,48]. Scleroderma
ﬁbroblasts display increased autophagy levels that provide the energy
required for the acquisition of the proﬁbrotic phenotype [46].
In rheumatoid arthritis, synovial ﬁbroblasts synthesize excessive
amounts of ECMand are resistant to apoptosis. In this setting, autophagy
promotes synovial ﬁbroblasts survival [47,49] and therefore perpetua-
tion of the injury.
ECM deposition by cancer-associated ﬁbroblasts in the tumor
microenvironment drives tumor recurrence and metastasis. Stromal
cells up-regulate autophagy and produce high energy nutrients that
fuel the adjacent cancer cells, thereby promoting tumor growth, pro-
liferation and metastasis [50,51]. Autophagy inhibition in the tumor
microenvironment has been proposed as a promising new anticancer
therapy [52].
Cardiac ﬁbroblasts regulate the structural, biochemical, mechani-
cal and electrical properties of the heart by regulating the homeosta-
sis of the ECM [53]. However, up-regulation of autophagy in cardiac
ﬁbroblasts has a beneﬁcial effect on cardiac ﬁbrosis. Beta-2 adrenergic
receptor stimulation in cardiac myoﬁbroblasts is associated with in-
creased autophagy levels and increased collagen degradation [41]
In renal ﬁbrosis, autophagy induction during renal injury protects
mesangial cells (MC), the ﬁbrogenic cell type in the kidney, and in-
creases their survival [54,55]. Disruption of the essential autophagy
gene Atg7 with speciﬁc siRNA or treatment with the autophagy inhib-
itor 3MA in cultured MC has been associated with decreased levels
of collagen type I (COL 1) [40]. Conversely, Beclin 1-deﬁcient MCs
(siBeclin1) exhibit accumulation of COL 1 when compared with
autophagy competent MC [56]. Therefore, this data suggest a poten-
tial dual role of autophagy during kidney injury as both inducer of
COL 1 synthesis and degradation.
6. Chemical modulators of autophagy
The recent progress made in elucidating autophagy regulation has
led to its implication in a wide range of human diseases. As a result,
pharmacological manipulation of the autophagy pathway has become
an attractive and promising target. Development of speciﬁc compounds
is necessary in order to better understand the molecular regulation of
the autophagic pathway and to identify new treatment strategies for
human diseases associated with autophagy deregulation.
Small molecules that enhance or inhibit autophagy may constitute
a useful pharmacological approach depending on the disease context.
Here we brieﬂy describe some of them.
6.1. Inhibitors of autophagy
Inhibition of the class III PI3K (Vps34) pathway can be achievedwith
drugs such as 3-MA, wortmannin, and LY294002 [57,58] (Table 2).Mechanism Compounds Current
clinical use?
Inhibition of the class III
PI3K (Vps34)
pathway
• 3-Methyladenine
• Wortmannin
• LY294002
Impairment of AV
fusion/alteration
of lysosomal pH
• Chloroquine • Antimalarial
• Baﬁlomycin A1 • Macrolide
antibiotic
Increase of cytosolic
Ca++ levels
• Thapsigargin
• Bay K8644
Inhibition of histone
deacetylase
• Trichostatin A
Interaction with AMPK • Dorsomorphin
• AICAR (5-aminoimidazole-
4-carboxyamide ribonucleoside)
Table 3
Chemical inducers of autophagy and their current clinical applications.
Mechanism Compound Current clinical use
mTORC-dependent
mTORC1-speciﬁc inhibition • Rapamycin • Immunosuppressant
• Perhexilene
• Niclosamide • Antihelminthic
• Amiodarone • Antiarrhythmic
• Rottlerin
Inhibition of both mTORC1
and mTORC2
• PP242
• Torin1
Inhibition of both class I PI3K
and mTORC1
• PI103
mTORC-independent
Reduction of intracellular
levels of IP3
• Lithium Mood stabilizers
• Carbamazepine
• Valproic acid
Regulation of cAMP–Epac–PLC-ε–IP3
and Ca2+–calpain–Gsα pathways
• Verapamil • Antihypertensive
• Loperamide • Antidiarrheal
• Nimodipine • Antihypertensive
• Pimozide • Antipsychotic
• Nitrendipine • Antihypertensive
• Clonidine • Antihypertensive, pain
management, anxiolytic
• Rilmenidine • Antihypertensive
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of the pH in the lysosome with drugs such as the antimalarial chloro-
quine and the macrolide antibiotic baﬁlomycin A1 are also effective
autophagy inhibitors [59,60].
Drugs such as thapsigarin and Bay K8644 that increase cytosolic
Ca2+ levels have been described as mTOR independent-inhibitors
of autophagy [61]
Trichostatin A is a histone deacetylase inhibitor that has been
identiﬁed as a promising compound able to reduce excessive levels
of autophagy without altering basal levels [62].
Dorsomorphin blocks autophagy via inhibition of AMPK [63];
however AICAR (5-aminoimidazole-4-carboxamide ribonucleoside),
an activator of AMPK, can also inhibit autophagy in hepatocytes
[64]. This demonstrates the complexity of the autophagy process
and the need to develop more selective targets.
6.2. Inducers of autophagy
Manipulation of the mTOR pathway is the most widely used strat-
egy to enhance autophagy. Although rapamycin is the classic example,
perhexilene, niclosamide, amoidarone and rottlerin inhibit mTORC1
but not mTORC2 [65,66]. PP242 and Torin1 inhibit both mTORC1 and
mTORC2 complexes in a selective ATP-competitive way [67] (Table 3).
Although PI3K plays an important role in controlling the mTOR
pathway, its pharmacological manipulation has not been extensively
explored. PI103 is a potent autophagy inducer that blocks the class I
PI3K and also mTORC1 in an ATP-competitive manner [68].
Autophagy can also be induced in an mTOR-independent manner.
The mood-stabilizing drugs lithium, carbamazepine and valproic
acid enhance autophagy by reducing the intracellular levels of IP3
[69]. Other drugs (verapamil, loperamide, nimodipine, pimozide,
nitrendipine, clonidine, rilmenidine) [61] regulate the cAMP–Epac–
PLC-ε–IP3 and Ca2+–calpain–Gsα pathways respectively and have
recently been identiﬁed as autophagy inducers [66].
For a more extensive overview of the small molecules regulating
autophagy we direct the reader to the outstanding review [64].
7. Conclusions
Mesenchymal cells are the key drivers of the ﬁbrogenic process
and share certain core properties and regulatory pathways among
tissues. Despite recent advances in our understanding of ﬁbroticdiseases, effective antiﬁbrotic therapies remain elusive. A better
understanding of mesenchymal cell biology and regulatory pathways
is needed to promote the development of new antiﬁbrotic drugs that
exploit autophagic pathways.References
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